<DOC>
	<DOCNO>NCT00546793</DOCNO>
	<brief_summary>The purpose study determine subcutaneous ( SC ) dose schedule veltuzumab establish NHL CLL patient confirm safety efficacy veltuzumab previously establish administer intravenously .</brief_summary>
	<brief_title>Ph I/II Study Subcutaneously Administered Veltuzumab ( hA20 ) NHL CLL</brief_title>
	<detailed_description>The first study veltuzumab give IV weekly NHL patient ( IM-T-hA20-01 ) show excellent tolerability even efficacy weekly intravenous dos low 80-120 mg/m2 4 consecutive week . These clinical result confirm experiment laboratory study . Laboratory study use Veltuzumab administer subcutaneously showed potent activity base B-cell depletion . The current study 's goal determine subcutaneous ( SC ) dose schedule veltuzumab establish patient NHL CLL</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>Histologically confirm diagnosis CD20 positive chronic lymphocytic leukemia ( CLL ) Either previously untreated relapsed Measurable disease ( least one lesion &gt; 1.5 cm NHL , ALC &gt; 5,000 CLL ) see full protocol additional criterion Previously untreated NHL patient Stage I II disease ( Ann Arbor classification ) Previously untreated CLL patient Stage 02 disease ( Rai classification ) unless specific treatment indication NCCN guideline exist ( symptomatic , recurrent infection , endorgan function , cytopenias steady disease progression ) . see full protocol additional criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>humanize anti-CD20 veltuzumab ( IMMU-106 ) administer subcutaneously</keyword>
</DOC>